Rationale  ||| S:0 E:10 ||| NN
for  ||| S:10 E:14 ||| IN
routine  ||| S:14 E:22 ||| JJ
and  ||| S:22 E:26 ||| CC
immediate  ||| S:26 E:36 ||| JJ
administration  ||| S:36 E:51 ||| NN
of  ||| S:51 E:54 ||| IN
intravenous  ||| S:54 E:66 ||| JJ
estrogen  ||| S:66 E:75 ||| NN
for  ||| S:75 E:79 ||| IN
all  ||| S:79 E:83 ||| DT
critically  ||| S:83 E:94 ||| JJ
ill  ||| S:94 E:98 ||| JJ
and  ||| S:98 E:102 ||| CC
injured  ||| S:102 E:110 ||| JJ
patients  ||| S:110 E:119 ||| NNS
In  ||| S:119 E:122 ||| IN
addition  ||| S:122 E:131 ||| NN
to  ||| S:131 E:134 ||| TO
a  ||| S:134 E:136 ||| DT
number  ||| S:136 E:143 ||| NN
of  ||| S:143 E:146 ||| IN
very  ||| S:146 E:151 ||| RB
compelling  ||| S:151 E:162 ||| JJ
clinical  ||| S:162 E:171 ||| JJ
observations ||| S:171 E:183 ||| NNS
,  ||| S:183 E:185 ||| ,
an  ||| S:185 E:188 ||| DT
extensive  ||| S:188 E:198 ||| JJ
body  ||| S:198 E:203 ||| NN
of  ||| S:203 E:206 ||| IN
extremely  ||| S:206 E:216 ||| RB
supportive  ||| S:216 E:227 ||| JJ
experimental  ||| S:227 E:240 ||| JJ
data  ||| S:240 E:245 ||| NN
has  ||| S:245 E:249 ||| VBZ
generated  ||| S:249 E:259 ||| VBN
a  ||| S:259 E:261 ||| DT
very  ||| S:261 E:266 ||| RB
persuasive  ||| S:266 E:277 ||| JJ
argument  ||| S:277 E:286 ||| NN
that  ||| S:286 E:291 ||| IN
intravenous  ||| S:291 E:303 ||| JJ
estrogen  ||| S:303 E:312 ||| NN
should  ||| S:312 E:319 ||| MD
be  ||| S:319 E:322 ||| VB
routinely  ||| S:322 E:332 ||| RB
administered ||| S:332 E:344 ||| VBN
,  ||| S:344 E:346 ||| ,
as  ||| S:346 E:349 ||| RB
soon  ||| S:349 E:354 ||| RB
as  ||| S:354 E:357 ||| IN
possible ||| S:357 E:365 ||| JJ
,  ||| S:365 E:367 ||| ,
to  ||| S:367 E:370 ||| TO
all  ||| S:370 E:374 ||| DT
persons  ||| S:374 E:382 ||| NNS
identified  ||| S:382 E:393 ||| VBN
as  ||| S:393 E:396 ||| IN
having  ||| S:396 E:403 ||| VBG
a  ||| S:403 E:405 ||| DT
critical  ||| S:405 E:414 ||| JJ
illness  ||| S:414 E:422 ||| NN
or  ||| S:422 E:425 ||| CC
injury ||| S:425 E:431 ||| NN
.  ||| S:431 E:433 ||| .
Although ||| S:433 E:441 ||| IN
,  ||| S:441 E:443 ||| ,
to  ||| S:443 E:446 ||| TO
date ||| S:446 E:450 ||| NN
,  ||| S:450 E:452 ||| ,
definitive  ||| S:452 E:463 ||| JJ
gold-standard  ||| S:463 E:477 ||| JJ
clinical  ||| S:477 E:486 ||| JJ
trials  ||| S:486 E:493 ||| NNS
are  ||| S:493 E:497 ||| VBP
lacking ||| S:497 E:504 ||| VBG
,  ||| S:504 E:506 ||| ,
what  ||| S:506 E:511 ||| WP
has  ||| S:511 E:515 ||| VBZ
made  ||| S:515 E:520 ||| VBN
this  ||| S:520 E:525 ||| DT
provocative  ||| S:525 E:537 ||| JJ
argument  ||| S:537 E:546 ||| NN
even  ||| S:546 E:551 ||| RB
more  ||| S:551 E:556 ||| JJR
convincing  ||| S:556 E:567 ||| NN
is  ||| S:567 E:570 ||| VBZ
the  ||| S:570 E:574 ||| DT
longstanding ||| S:574 E:586 ||| JJ
,  ||| S:586 E:588 ||| ,
documented  ||| S:588 E:599 ||| VBN
safety  ||| S:599 E:606 ||| NN
of  ||| S:606 E:609 ||| IN
intravenous  ||| S:609 E:621 ||| JJ
estrogen  ||| S:621 E:630 ||| NN
for  ||| S:630 E:634 ||| IN
various  ||| S:634 E:642 ||| JJ
illnesses  ||| S:642 E:652 ||| NNS
and  ||| S:652 E:656 ||| CC
conditions  ||| S:656 E:667 ||| NNS
as  ||| S:667 E:670 ||| IN
well  ||| S:670 E:675 ||| RB
as  ||| S:675 E:678 ||| IN
the  ||| S:678 E:682 ||| DT
relative  ||| S:682 E:691 ||| JJ
ease  ||| S:691 E:696 ||| NN
and  ||| S:696 E:700 ||| CC
inexpensive  ||| S:700 E:712 ||| JJ
cost  ||| S:712 E:717 ||| NN
of  ||| S:717 E:720 ||| IN
treatment ||| S:720 E:729 ||| NN
.  ||| S:729 E:731 ||| .
As  ||| S:731 E:734 ||| IN
such ||| S:734 E:738 ||| JJ
,  ||| S:738 E:740 ||| ,
even  ||| S:740 E:745 ||| RB
routine  ||| S:745 E:753 ||| JJ
prehospital  ||| S:753 E:765 ||| JJ
administration  ||| S:765 E:780 ||| NN
becomes  ||| S:780 E:788 ||| VBZ
extremely  ||| S:788 E:798 ||| RB
feasible  ||| S:798 E:807 ||| JJ
for  ||| S:807 E:811 ||| IN
a  ||| S:811 E:813 ||| DT
myriad  ||| S:813 E:820 ||| JJ
of  ||| S:820 E:823 ||| IN
conditions ||| S:823 E:833 ||| NNS
.  ||| S:833 E:835 ||| .
More  ||| S:835 E:840 ||| RBR
importantly ||| S:840 E:851 ||| RB
,  ||| S:851 E:853 ||| ,
the  ||| S:853 E:857 ||| DT
worldwide  ||| S:857 E:867 ||| JJ
magnitude  ||| S:867 E:877 ||| NN
of  ||| S:877 E:880 ||| IN
potential  ||| S:880 E:890 ||| JJ
patients  ||| S:890 E:899 ||| NNS
who  ||| S:899 E:903 ||| WP
could  ||| S:903 E:909 ||| MD
benefit  ||| S:909 E:917 ||| VB
is  ||| S:917 E:920 ||| VBZ
profound ||| S:920 E:928 ||| JJ
.  ||| S:928 E:930 ||| .
Even  ||| S:930 E:935 ||| RB
if  ||| S:935 E:938 ||| IN
estrogen  ||| S:938 E:947 ||| JJ
only  ||| S:947 E:952 ||| JJ
changes  ||| S:952 E:960 ||| NNS
the  ||| S:960 E:964 ||| DT
outcome  ||| S:964 E:972 ||| NN
in  ||| S:972 E:975 ||| IN
a  ||| S:975 E:977 ||| DT
relatively  ||| S:977 E:988 ||| RB
small  ||| S:988 E:994 ||| JJ
percentage  ||| S:994 E:1005 ||| NN
of  ||| S:1005 E:1008 ||| IN
applicable  ||| S:1008 E:1019 ||| JJ
cases ||| S:1019 E:1024 ||| NNS
,  ||| S:1024 E:1026 ||| ,
the  ||| S:1026 E:1030 ||| DT
potential  ||| S:1030 E:1040 ||| JJ
impact  ||| S:1040 E:1047 ||| NN
may  ||| S:1047 E:1051 ||| MD
still  ||| S:1051 E:1057 ||| RB
be  ||| S:1057 E:1060 ||| VB
of  ||| S:1060 E:1063 ||| IN
dramatic  ||| S:1063 E:1072 ||| JJ
proportions  ||| S:1072 E:1084 ||| NNS
in  ||| S:1084 E:1087 ||| IN
terms  ||| S:1087 E:1093 ||| NNS
of  ||| S:1093 E:1096 ||| IN
the  ||| S:1096 E:1100 ||| DT
absolute  ||| S:1100 E:1109 ||| JJ
number  ||| S:1109 E:1116 ||| NN
of  ||| S:1116 E:1119 ||| IN
lives  ||| S:1119 E:1125 ||| NNS
saved  ||| S:1125 E:1131 ||| VBN
and  ||| S:1131 E:1135 ||| CC
the  ||| S:1135 E:1139 ||| DT
resources  ||| S:1139 E:1149 ||| NNS
spared  ||| S:1149 E:1156 ||| VBN
worldwide ||| S:1156 E:1165 ||| NN
.  ||| S:1165 E:1167 ||| .
Resources  ||| S:1167 E:1177 ||| NNS
may  ||| S:1177 E:1181 ||| MD
be  ||| S:1181 E:1184 ||| VB
spared  ||| S:1184 E:1191 ||| VBN
not  ||| S:1191 E:1195 ||| RB
only  ||| S:1195 E:1200 ||| RB
in  ||| S:1200 E:1203 ||| IN
terms  ||| S:1203 E:1209 ||| NNS
of  ||| S:1209 E:1212 ||| IN
diminishing  ||| S:1212 E:1224 ||| VBG
the  ||| S:1224 E:1228 ||| DT
economic  ||| S:1228 E:1237 ||| JJ
impact  ||| S:1237 E:1244 ||| NN
of  ||| S:1244 E:1247 ||| IN
death  ||| S:1247 E:1253 ||| NN
and  ||| S:1253 E:1257 ||| CC
long-term  ||| S:1257 E:1267 ||| JJ
disability ||| S:1267 E:1277 ||| NN
,  ||| S:1277 E:1279 ||| ,
but  ||| S:1279 E:1283 ||| CC
also  ||| S:1283 E:1288 ||| RB
in  ||| S:1288 E:1291 ||| IN
terms  ||| S:1291 E:1297 ||| NNS
of  ||| S:1297 E:1300 ||| IN
preventing  ||| S:1300 E:1311 ||| VBG
extended  ||| S:1311 E:1320 ||| VBN
intensive  ||| S:1320 E:1330 ||| JJ
care  ||| S:1330 E:1335 ||| NN
unit  ||| S:1335 E:1340 ||| NN
stays  ||| S:1340 E:1346 ||| NNS
and  ||| S:1346 E:1350 ||| CC
treatment  ||| S:1350 E:1360 ||| NN
of  ||| S:1360 E:1363 ||| IN
preventable  ||| S:1363 E:1375 ||| JJ
complications  ||| S:1375 E:1389 ||| NNS
that  ||| S:1389 E:1394 ||| IN
result  ||| S:1394 E:1401 ||| NN
in  ||| S:1401 E:1404 ||| IN
longer  ||| S:1404 E:1411 ||| JJR
recovery ||| S:1411 E:1419 ||| NN
.  ||| S:1419 E:1421 ||| .
